Endoscopic Transthoracic Limited Sympathotomy for Palmar-Plantar Hyperhidrosis: Outcomes and Complications During a 10-Year Period

Atkinson, John L.D.; Fode-Thomas, Nicolee C.; Fealey, Robert D.; Eisenach, John H.; Goerss, Stephan J.

doi:10.4065/mcp.2011.0199

Cited by 61 publications

(55 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study, conducted by Atkinson et al ,6 postoperative pulmonary disfunction has been found to be very low in patients who underwent VATS, compared with those who underwent conventional thoracotomy.…”

Section: Discussionmentioning

confidence: 92%

Single incision thoracoscopic sympathectomy for hyperhidrosis

Ünal

Çıtgez

Battal³

et al. 2012

Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Single incision thoracoscopic sympathectomy for hyperhidrosis

Ünal

Çıtgez

Battal³

et al. 2012

Case Reports

View full text Add to dashboard Cite

“…Reported rates of CH after sympathectomy range from 30% to 90% 59–61. Severe CH is defined as CH troublesome enough that the patient regrets undergoing ETS 57. The incidence of severe CH after sympathectomy is approximately 35% 62.…”

Section: Surgerymentioning

confidence: 99%

“…In contrast with sympathectomy, sympathotomy does not include ganglionectomy 57. While the incidence of severe CH after sympathectomy is approximately 35%, the rate of this adverse event after sympathotomy is approximately only 1.3% 62.…”

Section: Surgerymentioning

confidence: 99%

Management of hyperhidrosis

Stashak¹,

Brewer

2014

CCID

View full text Add to dashboard Cite

Primary hyperhidrosis (HH), a condition of sweating in excess of thermoregulatory requirements, affects nearly 3% of the US population and carries significant emotional and psychosocial implications. Unlike secondary HH, primary HH is not associated with an identifiable underlying pathology. Our limited understanding of the precise pathophysiologic mechanism for HH makes its treatment particularly frustrating. However, a wide array of interventions for the treatment of HH have been implemented throughout the world. Herein, we discuss the most extensively studied therapeutic options for primary HH, including systemic oxybutynin, botulinum toxin injections, skin excision, liposuction–curettage, and sympathotomy/sympathectomy. We conclude with a discussion of possible future therapies for HH, including the applications of laser, microwave, and ultrasound technologies.

show abstract

“…CS is generally reported in 28-100% of cases during the early post-operation period, but 2 to 3 years after surgery its occurrence rate is reduced to 21%-47%. Although CS has a rather high prevalence, it is severe in only 0-14% of patients during the early postoperation period, and its severity declines with time (Table 1) [1,7,21,26,29,[33][34][35][36][37][38].…”

Section: Surgery Outcomes and Consequencesmentioning

confidence: 99%